Micro Pharmaceuticals
Market Cap
₹818 ₹818 Cr.
P/E
27.22
PEG
1.79
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base thesis lives or dies on phase-wise Pen Greenfield conversion into commercial sales, supported by new-market registrations and repeat local order flow for export and domestic supply

Bull path brings Pen lines live early and accelerates export conversion and utilization, pulling the export and local ramp forward

Bear path is triggered by Pen commissioning delays combined with weak export run-rates and collections, soft local offtake, and receivables and borrowing stress

Key Ratios

Debt to Equity
Debt to Equity
0.32
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
17.02 %
Institutions
Institutions
0.61 %
Market cap
Market cap
818 Cr
No. of Shareholders
No. of Shareholders
12,319
OPM (%)
OPM (%)
15.29 %
PE
PE
27.22
Prom Holding
Prom Holding
63.77 %
ROCE (%)
ROCE (%)
13.56
ROE (%)
ROE (%)
10.79
Sales
Sales
237 Cr
  • Kilitch Drugs(India)
  • Zim Laboratories
  • Anuh Pharma
Last updated on 28 Sep 2026
  • Kilitch Drugs is a pharma formulator making oral dosages, injectable vials and ampoules, eye and nasal products and nutraceuticals. It has a 35-year contract-manufacturing record.
  • It sells mainly on export registrations abroad, alongside domestic sales and government and private sales in Ethiopia.
  • Its mix has shifted hard toward export registration-led sales. Exports rose from 61% of standalone revenue in FY25 to about 70% in FY26.
  • Profit comes from export registration-led and domestic sales. Growth rests on the sterile campus at Pen and the Ethiopian antibiotic plant. Export quarters are lumpy.
  • In Ethiopia it has a 25% local price edge and a five-year tax holiday. Per management, it is the sole cephalosporin antibiotic supplier there.
  • It is building the sterile injectables campus at Pen. Work in progress was about ₹140 Cr in March 2026 against about ₹235 Cr FY26 revenue.
  • Working capital is stressed. Receivables were about ₹117 Cr at March 2026, about half of annual revenue. Bad-debt charges tripled in FY26.
  • It is in a build phase. Near-term profit depends on Pen commissioning. Management guides ₹500 Cr revenue and 22-24% EBITDA by FY27, over double FY26.
  • The Ethiopian plant has lost money for more than three years. The seller's market story per management has not yet produced a profit.
  • Sterile campus at Pen was May 2025; no update since
    adds 260M tablets, 31M vials and other planned capacity against nil. Ramp depends on getting work per management.
  • ₹500 Cr revenue target next management commentary
    management keeps or walks back the ₹500 Cr FY27 revenue and 22-24% EBITDA guide against ₹235 Cr in FY26.
  • Ethiopian plant turn to profit No timeline
    quarterly losses narrow from ₹2.87 Cr in Q1FY27. Repeat government orders resume.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
121
52W Range
High
268
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

6 Yes

Positive for this company

3 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

Customers

  • Abbott India Ltd.
  • Ajanta Pharma Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Procter & Gamble Health Ltd.

FAQs on Kilitch Drugs (India) Ltd. Business

Kilitch Drugs (India) Limited, based in Mumbai, is a pharmaceutical company focusing on manufacturing and marketing antibacterial parenteral formulations including Carbapenems, Cephalosporins, and anti malarials. It transferred some products to Akorn India Pvt. Ltd. in 2012.

Kilitch Drugs(India) major competitors are Zim Laboratories, Wanbury, Anuh Pharma, Shivalik Rasayan, Albert David, Prevest Denpro, Trident Lifeline.
Market Cap of Kilitch Drugs(India) is ₹755 Crs.
While the median market cap of its peers are ₹629 Crs.

Kilitch Drugs(India) seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release May Nov Dec Mar Mar Jun Sep
Investor Presentation
Conference Call Mar Mar
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material